# A Study of ILB2109 in Patients With Advanced Solid Malignancies

> **NCT05278546** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Innolake Biopharm** · enrollment: 48 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** ILB2109

## Key facts

- **NCT ID:** NCT05278546
- **Lead sponsor:** Innolake Biopharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-11
- **Primary completion:** 2024-12
- **Final completion:** 2025-02
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-11-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05278546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05278546, "A Study of ILB2109 in Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05278546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*